RxDoctor Payments Data

Cecilia O Dowd, MD

Family Medicine · Reno, NVNPI 1154414795

Payments from drug & device makers

$1,519in general payments, 2019–2025

Across 81 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$206
  • Johnson & Johnson$142
  • Lilly USA, LLC$138
  • Boehringer Ingelheim$131
  • Dexcom, Inc.$125
  • Pfizer$125
  • plus $651 from 12 others

What the payments were for

  • Food & beverage$1,50799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,519 in reported general payments places this provider in the 75th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$120,822
Medicare patients
284
Services billed
2,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$96,282
XareltoRivaroxaban36$57,162
MounjaroTirzepatide47$48,890
JardianceEmpagliflozin28$46,519
TrulicityDulaglutide31$38,519
EliquisApixaban24$31,037
MyrbetriqMirabegron23$26,742
Tresiba Flextouch U-100Insulin Degludec23$16,573
SymbicortBudesonide/Formoterol Fumarate11$4,463
SynthroidLevothyroxine Sodium58$4,400
Levothyroxine Sodium195$2,819
Rosuvastatin Calcium161$2,308
Estradiol29$2,189
Atorvastatin Calcium194$2,096
Famotidine39$1,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$119$96,28281 claims
Lilly USA, LLCMounjaro, Trulicity$138$87,40978 claims
Johnson & JohnsonXarelto$142$57,16236 claims
Boehringer IngelheimJardiance$131$46,51928 claims
PfizerEliquis$125$31,03724 claims
AbbVieSynthroid, Armour Thyroid$92$5,46570 claims
AstraZenecaSymbicort$206$4,46311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →